Budesonide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is released as a non-halogenated glucocorticoid free alcohol with the molecular formula C25H34O6 and relative molecular mass 430.53 g/mol. The material is supplied under two formulation-critical designations: BUD-API-M, a micronized grade with laser-diffraction particle size controlled per Ph.Eur. 2.9.31, and BUD-API-CG, a controlled-granule grade intended for dry blending, roller compaction, or pellet layering. Release testing follows the current European Pharmacopoeia and USP budesonide monographs, including assay by liquid chromatography (Ph.Eur. 2.2.29; USP <621>) and loss on drying by Ph.Eur. 2.2.32 / USP <731>. The oral grade is non-sterile with microbiological quality controlled per Ph.Eur. 2.6.12/2.6.13; the injectable grade is processed under aseptic conditions and tested for bacterial endotoxins per Ph.Eur. 2.6.14 / USP <85>. Differences from non-pharmacopoeial corticosteroid powders include documented ICH Q3C residual solvent control, ICH Q3D elemental impurity risk management, and particle size distribution appropriate to the dosage form rather than a single unspecified milled powder.

Does Micronization Create a Trade-Off Between Dissolution Rate and Flowability in Low-Dose Tablet Manufacture?

For low-dose oral tablet manufacture, the principal constraint is the combination of low mass per unit and poor powder flow. Budesonide tablets are commonly formulated at 3 mg, 6 mg, or 9 mg per unit. Direct compression of a micronized grade may produce adequate dissolution surface area but can fail flowability tests; bulk and tapped density values measured according to Ph.Eur. 2.9.34 often produce Hausner ratios above 1.25 and Carr index values above 25%, indicating cohesive flow. On rotary tablet presses, this manifests as weight variation and segregation if the press is run at high turret speed without a force feeder. Production-scale resolution uses a pre-blend of the API with lactose monohydrate, delumping through a 0.5 mm screen, and main blending in a bin blender at 12–25 rpm for a duration established by blend uniformity testing. Content uniformity is evaluated per Ph.Eur. 2.9.40 / USP <905>; for a 9 mg dose, dosage-unit recovery must meet the acceptance value AV ≤15 in Stage 1. Direct compression may be suitable only when the drug load exceeds 5% w/w; below that, wet or dry granulation is normally required to prevent segregation. Aqueous wet granulation must be followed by fluid-bed drying to a loss-on-drying target not exceeding 1.5% w/w, because residual moisture can alter the dissolution kinetics of the immediate-release tablet. These processing boundaries are batch-specific and must be revalidated when the micronized grade particle size distribution shifts.

In capsule and granule processing, budesonide is not typically loaded as a plain powder mixture because the required site-specific release profile in Crohn’s disease therapy demands gastro-resistant pellet or granule coatings. The active ingredient is layered onto sugar spheres or spray-dried onto microcrystalline cellulose carrier cores, then coated with methacrylic acid–ethyl acrylate or methacrylic acid–methyl methacrylate copolymers. Dissolution thresholds are selected in the pH 5.5 to pH 7.0 range to release drug in the distal ileum and ascending colon; the release mechanism is primarily pH-dependent, not immediate disintegration. Coated granules are filled into hard gelatin or HPMC capsules; capsule content uniformity is verified per Ph.Eur. 2.9.40 / USP <905>, and dissolution is evaluated using a two-stage pH-shift method with USP apparatus I or II at 37 ± 0.5 °C per Ph.Eur. 2.9.3 / USP <711>. During fluid-bed coating, inlet air temperature is controlled to maintain bed temperature below the glass transition point of the coating polymer; a process target of 25–30 °C bed temperature is used for aqueous methacrylic acid copolymer dispersions, while the API remains in the core. No single universal dissolution acceptance criterion exists; each marketing authorization holder specifies sampling times and percent released in pH-shift buffers. The Budesonide Pharma Grade API supplied for this route requires a narrow particle-size distribution to avoid irregular pellet layering and dust losses in the Wurster column.

Pharmacopoeial Release Limits for Budesonide API and the Injectable-Grade Endotoxin Burden

Assay and organic purity are controlled by liquid chromatography with ultraviolet detection. The compendial assay limit is 98.0–102.0% calculated with reference to the dried substance, and residual solvents are controlled under ICH Q3C; the actual solvent list must include any Class 2 solvents used in the final crystallization. Loss on drying is typically controlled at ≤0.5% and sulfated ash/residue on ignition at ≤0.1%. Elemental impurities are managed according to ICH Q3D; for an oral and injectable drug substance, the permitted daily exposure is derived from the finished-product maximum daily dose, not a fixed API concentration. The injectable grade additionally requires bacterial endotoxin testing by Ph.Eur. 2.6.14 or USP <85>, with a limit defined by the product monograph and patient dose. Because budesonide is practically insoluble in water, terminal sterile filtration of a solution is not feasible; injectable suspensions are prepared from sterile or aseptically processed API and must meet particulate matter limits under Ph.Eur. 2.9.19 / USP <788>. Table 1 summarizes the release and formulation-critical control matrix.

Because budesonide is practically insoluble in water, injectable compounding differs fundamentally from the preparation of dexamethasone sodium phosphate solution. The injectable product is a suspension; particle size, crystal habit, zeta potential, and sedimentation volume control syringeability and dose accuracy. The micronized BUD-API-M grade is released with a particle-size distribution specification and a quantitative assay on the cohesive solid. On aseptic filling lines, the suspension is continuously stirred in jacketed stainless-steel vessels at 2–8 °C to reduce crystal growth and microbial proliferation; the fill volume and in-process resuspendability are monitored because settling can cause dose nonuniformity. Terminal steam sterilization of the suspended API is not universally applicable because the high surface area can promote agglomeration and crystal habit changes after autoclaving. Dry-heat sterilization may be used only when validated for particle-size stability; otherwise, aseptic processing of pre-sterile API is required. The injectable grade cannot be interchanged with oral-grade material simply by filtration or autoclaving, because non-sterile oral API carries endotoxin and particulate burdens that are not acceptable for parenteral administration.

During dry granulation by roller compaction for budesonide tablets, the API’s compactability is affected by its crystalline habit. The compacted ribbons are milled through an oscillating granulator with 0.8–1.0 mm screen; fine fractions below 75 µm are recompacted. Ribbon density is controlled by compaction force 8–12 kN/cm and roll speed 2–6 min⁻¹; the resulting granules are blended with crospovidone and magnesium stearate, but only after pre-blending and lubrication for 3–5 min to limit over-lubrication. Dissolution failures in low-dose budesonide tablets have been traced to excessive magnesium stearate coating of the slightly water-soluble API; therefore lubricant concentration is kept at 0.5–1.0% w/w and screened. Direct compression and dry granulation both require humidity control below 30% RH in the processing area because the micronized powder picks up surface moisture and loses flowability.

Published data for this specific configuration is limited; therefore route-specific particle size and dissolution relationships are established per batch by correlation of laser diffraction D10/D50/D90 with product dissolution at 37 °C in pH 6.8 phosphate buffer using USP apparatus II at 50 rpm. This correlation avoids setting a universal D90 limit that may not predict in vivo performance.

When Gastro-Resistant Coating Determines Capsule and Granule Performance

When the formulation relies on pH-dependent methacrylic acid copolymers, the API particle size and surface morphology influence the coating efficiency and the lag time after gastric emptying. A coarse grade with large irregular crystals may create surface protrusions through the polymer coat, leading to premature moisture ingress and dose dumping at low pH. The consequence is observed in dissolution testing as more than 10% released in 0.1 M HCl after 2 h before the pH-shift stage; a robust gastro-resistant product should release less than 10% in the acid stage according to common enteric-coating acceptance criteria, although the exact limit is product-specific. Coated granules are typically charged into a Wurster fluid-bed coater with a bottom spray nozzle; process variables include atomization pressure 1.5–2.5 bar, inlet air temperature 45–55 °C, and product bed temperature 28–32 °C for aqueous dispersions. Spray drying or wet milling may be used before coating to remove particles larger than 150 µm if the target core size is 500–1000 µm. Release testing uses USP apparatus I or II with pH-shift media; the specification is not defined by the API monograph but by the finished-product dossier. The API manufacturer therefore provides a particle-size distribution certificate and a bulk-density value so that the same grade can be used across multiple coating campaigns without redeveloping the wetting and layering process.

Differences From Halogenated Corticosteroid APIs in Oral and Parenteral Use

Comparative pharmacopoeial and clinical use data differentiate budesonide from dexamethasone, prednisolone, and budesonide prodrugs. Budesonide is a non-halogenated glucocorticoid free alcohol with relative molecular mass 430.53 g/mol; dexamethasone base has 392.46 g/mol and prednisolone has 360.44 g/mol. Unlike dexamethasone sodium phosphate and methylprednisolone sodium succinate, budesonide has no commercially equivalent water-soluble ester salt that allows direct intravenous solution injection; the free alcohol is used as a suspension where injectable approval exists. Oral controlled-release budesonide formulations are used because extensive first-pass metabolism in the intestinal mucosa and liver limits systemic exposure; published product information places systemic bioavailability of oral budesonide controlled-release at approximately 10% compared with substantially higher availability for conventional prednisolone and dexamethasone. This metabolic profile reduces hypothalamic-pituitary-adrenal suppression but also means that the drug is unsuitable for acute systemic corticosteroid replacement where immediate high plasma concentration is required. Budesonide’s 16α,17α-acetal group distinguishes it from ciclesonide, which is an inhaled prodrug; budesonide is active as the parent compound. Tablets, capsules, and granules of budesonide are therefore selected for local intestinal anti-inflammatory activity rather than systemic glucocorticoid replacement. The API grade for these products must be characterized by route-specific particle size, dissolution-linked surface area, and strict organic purity because the corticosteroid is given at low mass per unit.